Cargando…

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest

BACKGROUND: Previous studies on brain functional alterations associated with antidepressants for major depressive disorder (MDD) have produced conflicting results because they involved short treatment periods and a variety of compounds. METHODS: Resting-state functional magnetic resonance imaging sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Shihong, Li, Wei, Zhou, Yang, Ren, Hongwei, Lin, Guorong, Zhang, Sheng, Xiang, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277001/ https://www.ncbi.nlm.nih.gov/pubmed/35845440 http://dx.doi.org/10.3389/fpsyt.2022.950885

Ejemplares similares

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Abnormal degree centrality values as a potential imaging biomarker for major depressive disorder: A resting-state functional magnetic resonance imaging study and support vector machine analysis
por: Lin, Hang, et al.
Publicado: (2022)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
por: Bennabi, Djamila, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
por: Mattingly, Gregory W., et al.
Publicado: (2022)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023)

Disrupted Regional Homogeneity in Major Depressive Disorder With Gastrointestinal Symptoms at Rest
por: Yan, Meiqi, et al.
Publicado: (2021)

Abnormalities in Electroencephalographic Microstates Among Adolescents With First Episode Major Depressive Disorder
por: He, Yuqiong, et al.
Publicado: (2021)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
por: Moon, Seok Woo, et al.
Publicado: (2023)

Decreased Connectivity in Precuneus of the Ventral Attentional Network in First-Episode, Treatment-Naïve Patients With Major Depressive Disorder: A Network Homogeneity and Independent Component Analysis
por: Luo, Liqiong, et al.
Publicado: (2022)

Disrupted Regional Homogeneity in Melancholic and Non-melancholic Major Depressive Disorder at Rest
por: Yan, Meiqi, et al.
Publicado: (2021)

Abnormal degree centrality in first-episode medication-free adolescent depression at rest: A functional magnetic resonance imaging study and support vector machine analysis
por: Guo, Xin, et al.
Publicado: (2022)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
por: Segura-Garcia, Cristina, et al.
Publicado: (2021)

First-Episode Patients Report Cognitive Difficulties in Executive Functioning 1 Year After Initial Episode of Major Depressive Disorder
por: Schmid, Marit, et al.
Publicado: (2021)

Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug naïve major depressive disorder
por: Hu, Jieqiong, et al.
Publicado: (2023)

Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
por: Kotzalidis, Georgios D., et al.
Publicado: (2021)

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
por: Di Nicola, Marco, et al.
Publicado: (2023)

Thyroid dysfunction in young, first-episode and drug-naïve patients with major depressive disorder: prevalence and associated clinical factors
por: Wu, Jinbo, et al.
Publicado: (2023)

Prevalence and associated clinical factors for overweight and obesity in young first-episode and drug-naïve Chinese patients with major depressive disorder
por: Zhang, Jian-Jun, et al.
Publicado: (2023)

Alternations of White Matter Structural Networks in First Episode Untreated Major Depressive Disorder with Short Duration
por: Lu, Yi, et al.
Publicado: (2017)

Desynchronized white matter function and structure in drug-naive first-episode major depressive disorder patients
por: Guo, Qinger, et al.
Publicado: (2023)

Volumetric assessment of individual thalamic nuclei in patients with drug-naïve, first-episode major depressive disorder
por: Chibaatar, Enkhmurun, et al.
Publicado: (2023)

Association of Lipid Profile and Suicide Attempts in a Large Sample of First Episode Drug-Naive Patients With Major Depressive Disorder
por: Ma, Yue-Jiao, et al.
Publicado: (2020)

Abnormal Reginal Homogeneity in Left Anterior Cingulum Cortex and Precentral Gyrus as a Potential Neuroimaging Biomarker for First-Episode Major Depressive Disorder
por: Song, Yan, et al.
Publicado: (2022)

Early Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sertraline in Adolescents With First-Episode Major Depressive Disorder
por: Chen, Haisi, et al.
Publicado: (2022)

Association of Subclinical Hypothyroidism With Anxiety Symptom in Young First-Episode and Drug-Naïve Patients With Major Depressive Disorder
por: Yang, Ruchang, et al.
Publicado: (2022)

Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder
por: Qiu, Tian, et al.
Publicado: (2023)

Adjunctive repetitive transcranial magnetic stimulation for adolescents with first-episode major depressive disorder: a meta-analysis
por: Sun, Chen-Hui, et al.
Publicado: (2023)

Abnormal dynamic functional connectivity of thalamic subregions in patients with first-episode, drug-naïve major depressive disorder
por: Zheng, Yanting, et al.
Publicado: (2023)

Gender differences in the association between anxiety symptoms and thyroid hormones in young patients with first-episode and drug naïve major depressive disorder
por: Zhao, Ying, et al.
Publicado: (2023)

Metabolic Profiling in Bipolar Disorder Patients During Depressive Episodes
por: Ren, Yan, et al.
Publicado: (2020)

Subcortical Brain Volumes Relate to Neurocognition in First-Episode Schizophrenia, Bipolar Disorder, Major Depression Disorder, and Healthy Controls
por: Shi, Jing, et al.
Publicado: (2022)

Volumetric Deficit Within the Fronto-Limbic-Striatal Circuit in First-Episode Drug Naïve Patients With Major Depression Disorder
por: Zhang, Yiran, et al.
Publicado: (2021)

Reduced Brain Gray Matter Volume in Patients With First-Episode Major Depressive Disorder: A Quantitative Meta-Analysis
por: Zheng, Ruiping, et al.
Publicado: (2021)

Co-expression network of mRNA and DNA methylation in first-episode and drug-naive adolescents with major depressive disorder
por: Tao, Yuanmei, et al.
Publicado: (2023)

Association between triglyceride glucose index and suicide attempts in patients with first-episode drug-naïve major depressive disorder
por: Liu, Junjun, et al.
Publicado: (2023)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4us6paqnu2nhhv63n6p103816u